Anti-integrin therapy for inflammatory bowel disease

doi:10.3748/wjg.v24.i17.1868

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15324)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

1330

HTML

11407

Figures (1-2)

462

Tables (1-2)

217

Sum=13416

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

960

Download

948

Sum=1908

May 7, 2018 (publication date) through Jun 29, 2024

Times Cited of This Article

Times Cited (81)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. May 7, 2018; 24(17): 1868-1880
Published online May 7, 2018. doi: 10.3748/wjg.v24.i17.1868

Full Size Figure Download Figure

Figure 2 Therapeutic targets of anti-integrin agents[14]. VCAM-1: Vascular cellular adhesion molecule-1; MadCAM-1: Mucosal addressin cellular adhesion molecule-1.

Citation: Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol 2018; 24(17): 1868-1880
URL: https://www.wjgnet.com/1007-9327/full/v24/i17/1868.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i17.1868